Ad blocking detected

Thank you for visiting CanadianInsider.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Ultra Club
$432/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads
JOIN THE CLUB

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

Avicanna Inc. (T:AVCN)

Business Focus: Biotechnology & Medical Research (NEC)

INK Edge Outlook

Insider Chart - Past 6 Months

Insider Filings

Latest 10 SEDI filings for AVCN within the last 6 months
Loading...
See all filings within the past 6 months

Company News

Sep 23, 2024 07:25 ET
Avicanna Announces Medical Cannabis Real World Evidence Study through MyMedi.ca  
Avicanna Inc. (“Avicanna” or the “Company) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the development, manufacturing, and commercialization of plant-derived cannabinoid-based products is pleased to announce a...
Read full article
Aug 30, 2024 07:30 ET
Avicanna Announces Repayment of Debentures
Avicanna Inc. (“Avicanna” or the “Company”) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a commercial stage, international biopharmaceutical company focused on the development advancement, and commercialization of evidence-based, cannabinoid-based...
Read full article
See more news stories

Valuation Ratios

Industry
Sector
Beta
1.52
--
--
Price to Sales - TTM
1.20
5.21
3.30
Price to Book - most recent quarter
833.25
2.59
2.09
Price to Cash Flow per share - TTM
--
3.48
11.65
Price to Free Cash Flow per share - TTM
--
15.21
15.90
See all valuations

Short Report

Date Number of Shares Shorted Net Change
Oct 15, 2024 228,893 -1,408
Sep 30, 2024 230,301 42,763
Sep 15, 2024 187,538 -49,500
See Short Report

Business Summary

Sector:  Healthcare Industry:  Biotechnology & Medical Research

Avicanna Inc. is a Canada-based commercial-stage international biopharmaceutical company. The Company's scientific platform commercializes over thirty products across various market segments: Medical Cannabis & Wellness Products (RHO Phyto), Pharmaceutical Pipeline and Medical Cannabis Care Platform (MyMedi.ca). RHO Phyto formulary offers a diverse range of proprietary formulations, including oral, sublingual, topical and transdermal delivery. It has developed a pipeline of patent-pending drug candidates that are indication specific and in various stages of clinical development and commercialization. These cannabinoid-based drug candidates look to address unmet medical needs in the areas of dermatology, chronic pain and various neurological disorders. Its first pharmaceutical preparation (Trunerox) is in the drug registration stage in South America. MyMedi.ca is a medical cannabis care platform that serves medical cannabis patients' needs and enhances the patient's journey.

See business summary

 

Twitter

Search (past week) for $AVCN.CA

  • No tweets found